Business
BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023
Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned
About this update from Bioatla, Inc.
[{"type":"text","content":"Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion of the IASLC conferenceR&D day planned for December 13, 2023, to discuss BA3071 (CAB-CTLA-4) Phase 1/2 basket trialManagement to host third quarter 2023 financial results conference call and webcast on Tuesday, November 7, 2023 at 4:30 PM Eastern Time SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today provided guidance on near-term milestones and announced that it plans to host a conference call and webcast on Tuesday, November 7, 2023 at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2023 and provide business highlights. Third Quarter 2023 Conference Call and Webcast InformationDate: Tuesday, November 7, 2023Time: 4:30 p.m. ETWebcast Link: https://viavid.webcasts.com/starthere.jsp?ei=1635568&tp_key=63f5901bb0Dial-in Numbers: (888) 886-7786 (domestic), (416) 764-8658 (international)Conference ID: 05202391 The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website. About BioAtla, Inc.BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 700 patents filed, more than 400 of which have been issued. Broad paten...